Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger

Stocks Yahoo Finance By Yahoo Finance 30 Jun 2026 10:53 1 min read

Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger

Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger

Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger

Read the full story on Yahoo Finance → Opens the original article on finance.yahoo.com

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.